Literature DB >> 3899407

Quantification of apolipoprotein C-III in serum by a noncompetitive immunoenzymometric assay.

D Parsy, V Clavey, C Fievet, I Kora, P Duriez, J C Fruchart.   

Abstract

We used a noncompetitive immunoenzymometric assay to measure the concentration of total apolipoprotein C-III in human sera. Affinity-purified antibodies to apolipoprotein C-III were adsorbed to the surface of microtiter plates. After washing, this solid-phase antibody was incubated with antigen (serum from fasting subjects), washed, and then incubated with peroxidase-labeled purified antibodies to apolipoprotein C-III. After a last washing, the bound label was assayed, providing a direct measurement of the antigen. Optimized technical conditions for the assay yielded assay CVs of 3.5 and 5.6% for within- and between-run precision, respectively. Analytical recovery of apolipoprotein C-III added to a serum was quantitative (97%). This noncompetitive assay can be used to measure apolipoprotein C-III in different lipoprotein fractions (very-low or high-density fractions) and yields values that compare favorably with those obtained by electroimmunoassay (r = 0.94). The assay offers several advantages over existing techniques--sensitivity, specificity, simplicity, and no use of radioisotopes--and hyperlipemic samples can be used.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3899407

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  3 in total

1.  Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids.

Authors:  N Vu-Dac; P Gervois; I P Torra; J C Fruchart; V Kosykh; T Kooistra; H M Princen; J Dallongeville; B Staels
Journal:  J Clin Invest       Date:  1998-08-01       Impact factor: 14.808

2.  Efficacy of a low dose-range of fluvastatin (XU 62-320) in the treatment of primary hypercholesterolaemia. A dose-response study in 431 patients. The French-Dutch Fluvastatin Study Group.

Authors:  B Jacotot; J D Banga; P Pfister; M Mehra
Journal:  Br J Clin Pharmacol       Date:  1994-09       Impact factor: 4.335

3.  Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates.

Authors:  B Staels; N Vu-Dac; V A Kosykh; R Saladin; J C Fruchart; J Dallongeville; J Auwerx
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.